

Evaluating the feasibility and acceptability of a time limited anxiety in bipolar disorder

Submission date 28/03/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/03/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 13/03/2020	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Steve Jones

Contact details
Spectrum Centre for Mental Health Research
School of Health and Medicine
Lancaster University
Lancaster
United Kingdom
LA1 4YT
+44 (0)1524 593 382
s.jones7@lancaster.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
9419

Study information

Scientific Title

A randomised controlled trial evaluating the feasibility and acceptability of a time limited anxiety intervention in bipolar disorder

Study objectives

This study aims to evaluate the feasibility and acceptability of a newly adapted, time limited, psychological intervention for anxiety and bipolar disorder. The intervention has been developed in collaboration with service users and health professionals in earlier phases of this research and is based on current, evidence based cognitive behavioural therapy interventions for anxiety and bipolar disorder.

The principle objectives of this study are to evaluate the feasibility of recruiting participants into this study and of delivering this intervention to individuals who experience anxiety and bipolar disorder. The acceptability of the intervention to those who receive it will also be evaluated.

A secondary objective is to assess if the intervention is likely to be clinically effective in reducing anxiety and mood symptoms for individuals with bipolar disorder and concurrent anxiety. These objectives will be evaluated by monitoring recruitment and retention into the study, eliciting feedback from participants in the treatment arm of the trial, and measuring anxiety and mood symptoms at baseline and follow-up time points to evaluate if the intervention is likely to be effective at reducing mood and anxiety symptoms.

Please note that as of 13/11/2012, the anticipated end date of this trial was updated from 30/04/2011 to 24/01/2014.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North West Lancaster Research Ethics Committee ref:10/H1015/83 06/12/2010, amended 21/01/2011

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Bipolar disorder

Interventions

1. PARADES Anxiety, A psychological intervention for the joint treatment of anxiety and bipolar disorder
2. Follow Up Length: 20 month(s); Study Entry : Single Randomisation only
3. Participants who take part in this study will be randomly allocated to receive either the intervention, or their usual treatment.
4. Those in the intervention arm of the study will receive a maximum of 10 therapy sessions over a 4 month period, delivered by a trained psychological therapist, either at home or another place they feel comfortable.
5. All participants who take part in the study will be followed up both in person and over the telephone at regular 4 monthly intervals, over a period of 20 months and all participants will have the chance to share their personal experiences with the research team.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Recruitment & Retention: Timepoint(s): Baseline, 4, 8, 12, 16 and 20 months

Secondary outcome measures

Anxiety symptoms; Timepoint(s): Baseline, 4, 8, 12 16 and 20 months; Mood symptoms; Timepoint(s): Baseline, 4, 8, 12, 16 and 20 months.

Overall study start date

05/01/2011

Completion date

24/01/2014

Eligibility

Key inclusion criteria

1. Primary diagnosis of bipolar I or II disorder
2. Current experience of anxiety evidenced by a HADS-A score > 8
3. Aged 18+
4. Ability to understand spoken and written English to a level where participants are able to provide written informed consent and are able to participate in interviews, questionnaires and therapy sessions, where appropriate.
5. Male or Female

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 72; UK Sample Size: 72

Key exclusion criteria

1. Current experience of a manic, hypomanic, depressed or mixed episode, or experience of this in the past four weeks, although it is expected that some subsyndromal symptoms will be present
2. Current suicidal ideation with intent

Date of first enrolment

05/01/2011

Date of final enrolment

24/01/2014

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Spectrum Centre for Mental Health Research

Lancaster

United Kingdom

LA1 4YT

Sponsor information

Organisation

Lancaster University (UK)

Sponsor details

Physics Department
Lancaster University
Bailrigg
Lancaster
England
United Kingdom
LA1 4YW

Sponsor type

University/education

ROR

<https://ror.org/04f2nsd36>

Funder(s)

Funder type

Government

Funder Name

National Institute of Health Research (NIHR) (UK) - Programme for Applied Research

Funder Name

Ref: RP-PG-0407-10389

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/02/2013		Yes	No